Home > Neurology > MS Virtual 2020 > Treatment Strategies and Results > Low-dose rituximab as effective as high-dose, but safer

Low-dose rituximab as effective as high-dose, but safer

MS Virtual 2020
Results of a Spanish two-centre study suggest that low doses of rituximab are equally as effective as high doses, but have a superior safety profile [1]. A standardised treatment schedule for this anti-CD20 monoclonal antibody has yet to be established. The study authors think these results will change clinical practice. The efficacy and safety of 2 rituximab regimens were compared at 2 large MS centres in Barcelona and Girona. The Barcelona centre (BC; n=249) applied higher doses of rituximab than the Girona centre (GC; n=54). In the BC, at least 3 cycles of 2 g intravenously (IV) were followed by 1 g every 6 months; in the GC, a minimum of 1 cycle of 2 g IV was followed by 500 mg every 6 months. For the 303 study participants, clinical progression plus inflammatory activity was the main reason to start rituximab in the BC (45.8%) as well as the GC (79.6%). At baseline, mean annualised relapse rate (ARR) was 0.37 (BC) and 0.33 (GC), median EDSS was...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on